{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:58:26Z","timestamp":1789160306394,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ygyno.2014.09.017","type":"journal-article","created":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T22:59:16Z","timestamp":1412377156000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial"],"prefix":"10.1016","volume":"136","clinical-trial-number":[{"clinical-trial-number":"nct00565851","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01166737","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"ntr3337","registry":"10.18810\/dutch-trial-register"}],"author":[{"given":"Chee Khoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Hardy-Bessard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine","family":"Woie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Heywood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2014.09.017_bb0005","first-page":"326","article-title":"The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery","volume":"25","author":"Boente","year":"1998","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2014.09.017_bb0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jso.21652","article-title":"Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients","volume":"102","author":"Sehouli","year":"2010","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.017_bb0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2014.09.017_bb0020","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.20106","article-title":"Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?","volume":"100","author":"Zang","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2014.09.017_bb0025","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ygyno.2014.09.017_bb0030","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ygyno.2014.09.017_bb0035","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.bjc.6602466","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection","volume":"92","author":"Onda","year":"2005","journal-title":"Br J Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2014.09.017_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1525-1438.2005.00430.x","article-title":"The role of surgery in recurrent ovarian cancer","volume":"15","author":"Pfisterer","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.017_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejso.2004.08.016","article-title":"Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel\u2013platinum","volume":"31","author":"Gronlund","year":"2005","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2014.09.017_bb0050","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2014.09.017_bb0055","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0029-7844(02)01977-4","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"99","author":"Tay","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.09.017_bb0060","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1245\/s10434-006-9273-8","article-title":"Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer","volume":"14","author":"Benedetti Panici","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2014.09.017_bb0065","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.09.017_bb0070","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2014.09.017_bb0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2014.09.017_bb0080","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1023\/A:1008293802605","article-title":"Prognostic factors in salvage therapy of ovarian cancer","volume":"8","author":"Markman","year":"1997","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.017_bb0085","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.20.5.1232","article-title":"Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens","volume":"20","author":"Cantu","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.09.017_bb0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/annonc\/mdl376","article-title":"Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial","volume":"18","author":"Ferrero","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.017_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"29","key":"10.1016\/j.ygyno.2014.09.017_bb0100","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.09.017_bb0105","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/annonc\/mds538","article-title":"A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer","volume":"24","author":"Lee","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ygyno.2014.09.017_bb0110","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/bjc.2011.364","article-title":"Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer","volume":"105","author":"Lee","year":"2011","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.ygyno.2014.09.017_bb0115","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.09.017_bb0120","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"issue":"9375","key":"10.1016\/j.ygyno.2014.09.017_bb0125","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"ICON and AGO Collaborators","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ygyno.2014.09.017_bb0130","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1634\/theoncologist.2011-0373","article-title":"The role of secondary cytoreductive surgery in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers: a comparative effectiveness analysis","volume":"17","author":"Chuang","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ygyno.2014.09.017_bb0135","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ejca.2009.11.013","article-title":"Historical cross-trial comparisons for competing treatments in advanced breast cancer\u2014an empirical analysis of bias","volume":"46","author":"Lee","year":"2010","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2014.09.017_bb0140","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1245\/s10434-007-9547-9","article-title":"Primary tumor resection in stage IV breast cancer: consistent benefit, or consistent bias?","volume":"14","author":"Khan","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.ygyno.2014.09.017_bb0145","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1200\/JCO.2004.04.070","article-title":"Gene expression signature with independent prognostic significance in epithelial ovarian cancer","volume":"22","author":"Spentzos","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814013444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814013444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T21:21:16Z","timestamp":1538169676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814013444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0090825814013444"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}